- Home
- ASTS vs RPRX Comparison
ASTS vs RPRX Comparison
Compare ASTS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTS
- RPRX
- Stock Information
- Founded
- ASTS 2019
- RPRX 1996
- Country
- ASTS United States
- RPRX United States
- Employees
- ASTS N/A
- RPRX N/A
- Industry
- ASTS Telecommunications Equipment
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ASTS Consumer Discretionary
- RPRX Health Care
- Exchange
- ASTS Nasdaq
- RPRX Nasdaq
- Market Cap
- ASTS 19.4B
- RPRX 16.2B
- IPO Year
- ASTS N/A
- RPRX 2020
- Fundamental
- Price
- ASTS $70.38
- RPRX $40.42
- Analyst Decision
- ASTS Hold
- RPRX Strong Buy
- Analyst Count
- ASTS 8
- RPRX 3
- Target Price
- ASTS $54.32
- RPRX $46.00
- AVG Volume (30 Days)
- ASTS 13.1M
- RPRX 2.8M
- Earning Date
- ASTS 11-10-2025
- RPRX 11-05-2025
- Dividend Yield
- ASTS N/A
- RPRX 2.18%
- EPS Growth
- ASTS N/A
- RPRX N/A
- EPS
- ASTS N/A
- RPRX 1.77
- Revenue
- ASTS $4,892,000.00
- RPRX $2,349,553,000.00
- Revenue This Year
- ASTS $1,269.35
- RPRX $36.16
- Revenue Next Year
- ASTS $339.19
- RPRX $2.04
- P/E Ratio
- ASTS N/A
- RPRX $22.85
- Revenue Growth
- ASTS 249.43
- RPRX 3.69
- 52 Week Low
- ASTS $17.50
- RPRX $24.05
- 52 Week High
- ASTS $102.79
- RPRX $41.00
- Technical
- Relative Strength Index (RSI)
- ASTS 47.22
- RPRX 74.39
- Support Level
- ASTS $67.10
- RPRX $35.92
- Resistance Level
- ASTS $80.93
- RPRX $37.40
- Average True Range (ATR)
- ASTS 5.44
- RPRX 1.09
- MACD
- ASTS -2.29
- RPRX 0.26
- Stochastic Oscillator
- ASTS 16.15
- RPRX 91.94
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.